Simple lifestyle switch can slash colon cancer death by a third: 'It's better than any drug', according to top expert

An hour an a half of daily exercise could slash the risk of dying from colon cancer by more than a third, a pivotal trial has suggested.
Regular exercise has long been lauded as a crucial way to not only help stave off cancer, but also lower the chances of it spreading.
Now, groundbreaking research has shown patients with the disease saw their risk of death cut by 37 per cent by completing 10 hours of physical activity per week.
Anything from a brisk walk to high intensity interval training (HIIT) counted, meaning patients could also choose an activity that best fitted into their lifestyle.
Researchers, presenting the findings at the American Society of Clinical Oncology (ASCO) conference in Chicago today, said the study was 'one of the strongest bits of evidence that exercise works' to keep cancer at bay.
ASCO president and top cancer specialist Julie Gralow added that findings suggested exercise was 'better than a drug because it doesn't involve side effects'.
'This study shows it's not too late to start exercising even once diagnosed or if patients have started treatment.'
The research comes amid a rising ride of colon cancer striking people in their 20s, 30s and 40s —a phenomenon that has baffled doctors around the world.
Bowel cancer can cause you to have blood in your poo, a change in bowel habit, a lump inside your bowel which can cause an obstructions. Some people also suffer with weight loss a s a result of these symptoms
Over the last 30 years, young diagnoses of the disease have shot up by 80 per cent across the globe.
In the world-first trial, a group of international researchers tracked 889 people from six countries, including the UK, Australia and Canada, all of who had undergone surgery and chemotherapy for colon cancer that had spread to nearby lymph nodes but not reached other organs or tissues.
Half were prescribed a structured exercise programme, with the other half given health education materials alongside standard follow-up care and surveillance.
Those on the exercise regime received in-person coaching sessions every week for the first six months and once a month for the following two and a half years.
After five years, scientists found 80 per cent of volunteers in the exercise group remained cancer-free, compared to 74 per cent in the control contingent.
They also discovered the risk of death was a third lower in the exercise group.
The benefits remained after eight years—patients who stuck to the exercise programme had a 37 per cent lower risk of death, the authors reported in the New England Journal of Medicine.
Professor Vicky Coyle, UK lead researcher and clinical professor at Queen's University Belfast, said: 'We supported people to reach their weekly exercise target in a way that worked for them.
'This could be a long, brisk walk every day, but some patients were also doing circuit classes, cycling, swimming, and many other activities.
'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer.'
Dr Joe Henson, study co-author and associate professor in lifestyle medicine at the University of Leicester, added: 'I saw first hand that the exercise reduced fatigue, lifted people's mood, and boosted their physical strength.'
He added more research is needed to uncover the reasons behind the positive impact of exercise.
Previous research has suggested that exercise can trigger the release of chemicals in the blood that help the immune system hunt and destroy cancer cells.
Studies have also found that regular exercise reduces levels of inflammatory proteins in the body that are known to fuel the development of tumours.
Natasha Wood, now 40, who lives in London, was diagnosed with stage three colon cancer in 2015 at the age of just 30.
She had surgery, followed by six months of chemotherapy and has been in remission since 2016.
Ms Wood, who completed half-marathons before her diagnosis, was told by doctors that her baseline fitness level would improve her outcomes.
She said: 'The results of this trial corroborate my own personal experience whereby exercise has played a pivotal role both during treatment and in the years following.
'Throughout my treatment I continued to run, swim, cycle and lift weights, habits I've retained in the decade since.
'Exercise has been a cornerstone of my own healthy lifestyle and supported my physical and mental health in equal measure.'
The disease, the third most common cancer in the UK, is the same type that killed Dame Deborah James aged 40 in 2022.
Although the vast majority of diagnoses affect those aged over 50, rates in older age-groups has either declined or held stable while diagnoses in younger adults have soared over the last 30 years.
Doctors have suggested obesity, antibiotic over-use, mobile phone radiation and even invisible particles of plastic in drinking water are potential triggers.
However, a growing number of experts are also pointing to ultra-processed foods as a cause.
Around 32,000 cases of colon cancer are diagnosed every year in the UK and 142,000 in the US.
Symptoms include changes in bowel movements such as consistent and new diarrhoea or constipation, needing or feeling the need to poo more or less frequently and blood in the stool.
Stomach pain, a lump in the stomach, bloating, unexpected weight-loss and fatigue are among other common signs.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mail​

an hour ago

• Daily Mail​

NFL WAG Kristin Juszczyk put through grueling workout by husband Kyle

Couples who train together, stay together - that's if San Francisco 49ers star Kyle Juszczyk and wife Kristin are anything to go by. The fashion designer was put through her paces by her NFL beau Friday when she joined him in a grueling preseason workout. With the 2025 NFL season looming, the fullback began ramping up his preparation, taking to the field to run a series of drills and Kristin joined him for a 'dreaded 'come train with me"' day. Kristin, whose sports-inspired designs blew up after Taylor Swift wore one her custom puffer jackets to a Kansas City Chiefs game, shared a video to Instagram Friday showing her mimicking her husband's workouts to Survivor's 'Eye of the Tiger.' The entrepreneur, who married the Niner in 2019, copied Kyle as he tossed a medicine ball over his head and carried out a plank, crunches and sprints among other drills. On the whole, Kristin managed to hold her own, only occasionally losing her balance and failing to launch the weighted ball as far as her partner. View this post on Instagram A post shared by Kristin Juszczyk (@kristinjuszczyk) The fashion designer was captured mimicking her NFL beau's tough training regime Social media users were left impressed in the comment section, with one writing: 'Honestly crushed it.' 'He's not taking it easy on you at all lol,' another claimed, while a third added: 'Ok but you held your own during that workout- slaaaayed it!' The couple have endured a turbulent offseason, with Kyle, at one point, appearing likely to return to the Bay Area next season. Kyle was cut by the Niners in March following eight seasons with the team, only for San Francisco to sign him to a new contract just four days later. The 49ers had initially decided to cut Kyle, instead of paying him a $4.1m salary this season and up to an additional $500,000 in offseason workout and per-game roster bonuses. The team took on a $3.6m dead cap charge with the move but brought him back on a new two-year, $8million contract. He was also nearly cut last season but agreed to take a pay cut to stay in San Francisco. Juszczyk began his career with the Baltimore Ravens after they picked him in the fourth round of the 2013 NFL Draft. The 33-year-old was one of the first players signed after 49ers coach Kyle Shanahan and general manager John Lynch took over in 2017 and has been a key part of the offense since then thanks to his versatility. Kyle faced a turbulent offseason after being cut by the 49ers only to later sign a new deal In an era when few teams use fullbacks, Juszczyk has played about half the offensive snaps during his time with San Francisco and has made the Pro Bowl all eight seasons with the team and nine times overall. He was a first-team All-Pro in 2023 and second-teamer in 2024 after fullbacks were added back as a position for All-Pro the past two years. Juszczyk had 19 catches for 200 yards and two touchdowns last season, while also rushing for 26 yards and a touchdown. He has 184 catches for 1,895 yards and 13 touchdowns in eight seasons with the Niners, along with 237 yards rushing and six more touchdowns on the ground.

Times

an hour ago

• Times

My brother died at 33 — what I wish I'd known

I remember seeing the troubling spark of recognition in the psychologist's eyes when I told her that my late brother, Charlie, had schizophrenia. We were sitting in her office going through a never-ending pile of forms as part of my seven-year-old son Eddie's autism-assessment process, including my family history. 'Did you know,' she asked, 'that autism used to be known as childhood schizophrenia?' I remember the grating rough texture of the chair I was sitting on prickling against the back of my legs and feeling the inside of my stomach flip. We lost my big brother, Charlie, in 2004 when he was 33 and he hadn't had a particularly happy life. He had been diagnosed with schizophrenia at the age of 18 after a period of psychosis — he had been hearing voices and became convinced that a group of people were out to get him.

Reuters

2 hours ago

• Reuters

Novo Nordisk's experimental drug results in up to 24% weight loss

June 20 (Reuters) - Novo Nordisk ( opens new tab on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies, opens new tab to start next year. The company said side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar to other recent weight loss drugs. The full trial results were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Novo's head of development Martin Holst Lange said the Phase 3 amycretin program starting in 2026 will run "for a couple of years" after which the regulatory review process could start. The company earlier this month said it planned to start late-stage trials of the drug in the first quarter of 2026 after previously announcing the early-stage trial results. Amycretin has a dual-mode action. Like Novo's popular weight-loss drug Wegovy, it mimics the gut hormone GLP-1, but also targets receptors for a hunger-suppressing pancreatic hormone called amylin. Trial results showed that 20-milligram weekly injections of the drug helped overweight or obese patients without diabetes lose 22% of their weight over 36 weeks, with a 60-mg dose resulting in 24.3% weight loss. In the Phase 1 study of once-daily oral amycretin, patients received increasing doses, ranging from 3 mg to a final dose of 100 mg. Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4% on average, while those taking the maximum dose lost 13.1% of their weight, the company said. Novo said the weight loss did not plateau, suggesting that longer treatment could lead to greater weight loss. In a Lancet commentary, researchers not involved in the amycretin studies said that "while additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities." Commentators Tricia Tan, professor of metabolic medicine and endocrinology at Imperial College London, and endocrinologist Dr. Bernard Khoo, said studies directly comparing GLP-1 drugs like Novo's Ozempic to drugs like amycretin will be needed to definitively establish their added value and place in obesity management.